Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer

Cisplatin-based combination chemotherapy is the foundation for treatment of advanced bladder cancer (BlCa), but many patients develop chemoresistance mediated by increased Akt and ERK phosphorylation. However, the mechanism by which cisplatin induces this increase has not been elucidated. Among six...

Descripción completa

Detalles Bibliográficos
Autores principales: Steele, Thomas M., Tsamouri, Maria Malvina, Siddiqui, Salma, Lucchesi, Christopher A., Vasilatis, Demitria, Mooso, Benjamin A., Durbin-Johnson, Blythe P., Ma, Ai-Hong, Hejazi, Nazila, Parikh, Mamta, Mudryj, Maria, Pan, Chong-xian, Ghosh, Paramita M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267166/
https://www.ncbi.nlm.nih.gov/pubmed/37316561
http://dx.doi.org/10.1038/s41598-023-36774-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267166/
https://www.ncbi.nlm.nih.gov/pubmed/37316561
http://dx.doi.org/10.1038/s41598-023-36774-1

Ejemplares similares